**Introduction:** This case report depicts the role of oestrogen in initiating SLE in a patient which resolved on treatment. However she subsequently suffered another flare following receiving oestrogen based hormonal treatment during IVF. This lady experienced presentation of renal lupus in both a pregnant and non-pregnant state and different management was required on both occasions. The case highlights the importance of combined Obstetric and Rheumatology care in pregnancy in lupus patients. It also highlights the role of oestrogen based medications responsible for not only a flare of disease but also in initiating the disease.

**Case description:** A 25 year old female presented in 1997 with symptoms of arthralgia and a rash. The onset of the symptoms were following starting the oral contraceptive pill . Investigations revealed thrombocytopenia and slight lymphopenia. Serology showed positive ds-DNA and anti-cardiolipin antibodies. A renal biopsy confirmed lupus nephritis with diffuse proliferative glomerulonephritis. She was treated initially with Prednisolone and Azathioprine but with the emergence of renal disease she was then treated with IV Cyclophosphamide. Over the years she remained well with maintenance therapy including Azathioprine and Prednisolone. Azathioprine was withdrawn in 2003 and Hydroxychloroquine in 2006. In 2008 after being in remission for 7 years she decided to plan a family and went through a normal pregnancy with no flares of disease in puerperium. In October 2011 without discussion with the Rheumatology Team she planned another pregnancy via IVF with egg donation in Spain for which she was given high dose oestrogen for induction of ovulation. She was made aware of the possibility of her disease flaring due to the oestrogen content of medications which is known to cause mild to moderate flares of SLE. At this point of time her disease had been in remission for 12 years and serology was negative for antiphospholipid antibodies and Ro antibody. Despite being counselled previously regarding making contact with the high risk pregnancy team as soon as she became pregnant. In January 2012 she was reviewed at 15 weeks of pregnancy when she had significant proteinuria with a protein/creatinine ratio of 167 mg/mmol (0-15) .C4 levels were low and lymphocyte count were reduced to 1.11\*109 (1.5-3.5 \*109).Her renal function was normal.Her BP on this occasion was 140/78.She had no other symptoms of lupus. She was already taking Aspirin 75mg daily and Prednisolone 15mg daily was commenced. A renal biopsy showed evidence of type IV lupus nephritis following which she was reviewed at the combined rheumatology/renal/obstetric clinic at Birmingham Women's Hospital. She was commenced on Azathioprine 100mg daily, Hydroxychloroquine 200mg daily and Prednisolone was increased to 40mg. A glucose tolerance test at 26 weeks was advised as she was on Prednisolone and that she should have a growth scan at 24 weeks including uterine artery Doppler at 24 weeks and two weekly thereafter and that she should have blood counts and LFTs done weekly. Throughout pregnancy her renal function remained normal with improvement in her symptoms and PCR measurements. Complement levels had normalised and BP had returned to normal allowing reduction of Nifedipine. She was reviewed post --partum and was well in herself with slightly low C4 levels, normal ESR and PCR of 27mg/mmol. She remained well with no active symptoms and minimally raised PCR, mild lymphopenia and depressed C3 levels. Her Prednisolone was gradually reduced to stop by 2 years post-partum. She was last reviewed in March 2017 when she was still on Azathioprine and Hydroxychloroquine with persistent lymphopenia and low complements which hasn't seemed to change over the years but no suggestions of active lupus.

**Discussion:** This lady was diagnosed with SLE, symptoms of which commenced after taking the oral contraceptive pill. SLE is a chronic systemic autoimmune disease etiology of which involves a complex interaction between environmental, infectious and hormonal factors in a genetically susceptible subject.1Although it can affect any gender at any age, SLE is more common in women and incidence is increased in the reproductive years. Studies conducted in mouse model SLE show the role of sex hormones and its receptors in SLE onset and development, showing an increased renal disease associated with estrogen levels and that androgens are protective 2-7. This lady had an uneventful first pregnancy but she suffered a flare during her second pregnancy. The difference between the two pregnancies was that she underwent IVF in the second pregnancy which is known to be associated with flares of disease and close supervision and monitoring is recommended. High incidence of flares during pregnancy is reported in two prospective studies, mostly in the second trimester and post-partum8, 9. A retrospective case control-study a shows a higher flare rate in the pregnant group (0.093 of per patient per year) than among controls (0.049 per-patient per-year). In this study, majority of flares occurred during the second and third trimester and 8 weeks post delivery10. The increased level of estrogen during pregnancy could explain the risk of flare during this period and thus more reason to believe in the risk association between female hormones and SLE. Women who have SLE and APS and are infertile may choose to pursue IVF. However, there are concerns that IVF-associated hormonal manipulation may increase the risk for SLE flares, thrombosis, and pregnancy-related complications. Therefore such patients should undergo close monitoring and supervision in the same way as high risk pregnancies in other patients.

**Key learning points:** Oral contraceptives (OC) have been shown to be an etiologic risk factor for SLE and also associated with an increased risk of flares. Advice on the benefits and risks of OC is an important and difficult aspect of the care of women with SLE. This advice should be done based on the best evidence and always considering our particular subject and its changing risk profile. IVF associated hormonal treatments may lead to increased risks of flares of SLE and therefore such patients should be followed up closely. Lupus patients should see the high risk pregnancy team prior to conception and report to them immediately on confirming pregnancy.
